Strengthening Community-Driven Care
Funds implementation science projects embedding CME/CE to improve care and outcomes for RRMM patients eligible for BsAb or CAR T-cell therapy, focusing on measurable, sustainable impact in real-world settings.
Funder: Johnson & Johnson (Janssen)
Due Dates: June 30, 2026 (Implementation Science RRMM BsAb) | July 15, 2026 (Implementation Science CAR T)
Funding Amounts: Up to $275,000 per project; lower-cost proposals prioritized; project period up to 18 months
Summary: Funds independent medical education initiatives to improve care and equitable access in key therapeutic areas, with a 2026 focus on implementation science for RRMM and CAR T-cell therapy.
Key Information: General research projects are not eligible; only implementation science projects with embedded CME/CE education will be considered.
Description
Johnson & Johnson (Janssen) offers educational grants to support independent continuing medical education (CME/CE) initiatives that enhance the skills of healthcare professionals and promote equitable healthcare access. For 2026, the program specifically seeks implementation science projects that embed certified education within broader strategies to improve care for relapsed/refractory multiple myeloma (RRMM) patients eligible for bispecific antibody (BsAb) or CAR T-cell therapy. The aim is to foster measurable improvements in clinician behavior, care processes, and patient outcomes, particularly in community settings and populations facing barriers to care.
